Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

  • Technology appraisal guidance
  • TA47
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the committee

The following documentation and opinion were made available to the Committee:

  • Assessment report prepared by NHS Centre for Reviews and Dissemination and Centre for Health Economics:

    • A Systematic Review Update of the Clinical Effectiveness and Cost Effectiveness of Glycoprotein IIb/IIIa Antagonists and A Cost-effectiveness Model Comparing Alternative Management Strategies for the Use of Glycoprotein IIb/IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes

  • Manufacturer/sponsor submissions from:

    • Lilly

    • Schering Plough

    • MSD

  • Professional/specialist group submissions from:

    • British Cardiac Society and Royal College of Physicians (joint submission)

    • Royal College of General Practitioners

    • Department of Health and the Welsh Assembly Government

  • Patient/carer group submissions from:

    • British Heart Foundation

  • Expert perspective:

    • Dr J McLenachan, Dept of Cardiology, Leeds General Infirmary

    • Dr Charles Knight, Cardiology Dept, King George Hospital.